Search alternatives:
systemic decrease » systemic disease (Expand Search), systemic diseases (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
a decrease » _ decreased (Expand Search), _ decreases (Expand Search)
_ decrease » _ decreased (Expand Search)
a non » _ non (Expand Search)
systemic decrease » systemic disease (Expand Search), systemic diseases (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
a decrease » _ decreased (Expand Search), _ decreases (Expand Search)
_ decrease » _ decreased (Expand Search)
a non » _ non (Expand Search)
-
1
SLE decreases risk for hormonal cancers.
Published 2021“…An OR to the left of the solid line represents a reduction in risk. (a) Breast cancer incidence in female SLE cohort is significantly decreased by SLE status (OR 0.52, 95% CI 0.35, 0.74, p = 0.0036). …”
-
2
-
3
The decrease or inhibition of Hsp90 induced REST degradation.
Published 2019“…(D) The level of REST dramatically reduced in differentiated SH-SY5Y cells treated with GA (1 μM) or PU-H71 (50 nM) at 24 h. (E) The REST level decreased by GA more than 50% and (F) PU-H71 more than 80%, respectively. …”
-
4
-
5
-
6
-
7
Systemic inhibition of TGF-β decreases retinal smad2 phosphorylation <i>in vivo</i>.
Published 2013“…Lanes one and two are two retinal cDNA preparations. Lane three is a negative control with no RT enzyme. Immunohistochemical localization of pp-smad2 in retinas from (B) control (non infected animals) and (C) Ad-null and Ad-sEng-expressing mice (day 7) revealed pp-smad2 staining in nuclei of the ganglion cell layer (arrows) and the INL (arrowheads). sEng expression led to a decrease in the intensity of pp-smad2 staining. …”
-
8
-
9
-
10
Data_Sheet_1_Botulinum toxin A decreases neural activity in pain-related brain regions in individuals with chronic ocular pain and photophobia.docx
Published 2023“…On an individual level, 50% of subjects had decreased unpleasantness ratings in response to light stimulation compared to baseline (“responders,” n = 6), while 50% had equivalent (n = 3) or increased (n = 3) unpleasantness (“non-responders”). …”
-
11
Data_Sheet_2_Botulinum toxin A decreases neural activity in pain-related brain regions in individuals with chronic ocular pain and photophobia.docx
Published 2023“…On an individual level, 50% of subjects had decreased unpleasantness ratings in response to light stimulation compared to baseline (“responders,” n = 6), while 50% had equivalent (n = 3) or increased (n = 3) unpleasantness (“non-responders”). …”
-
12
Data_Sheet_1_Botulinum toxin A decreases neural activity in pain-related brain regions in individuals with chronic ocular pain and photophobia.docx
Published 2023“…On an individual level, 50% of subjects had decreased unpleasantness ratings in response to light stimulation compared to baseline (“responders,” n = 6), while 50% had equivalent (n = 3) or increased (n = 3) unpleasantness (“non-responders”). …”
-
13
Data_Sheet_2_Botulinum toxin A decreases neural activity in pain-related brain regions in individuals with chronic ocular pain and photophobia.docx
Published 2023“…On an individual level, 50% of subjects had decreased unpleasantness ratings in response to light stimulation compared to baseline (“responders,” n = 6), while 50% had equivalent (n = 3) or increased (n = 3) unpleasantness (“non-responders”). …”
-
14
Downregulation of DOM decreases the abundance of PER and TIM.
Published 2019“…Downregulation of DOM decreased PER levels at CT1-5 and CT17-21. (Scale bar: 50 um.) …”
-
15
Time allocation may not decrease with price for a non-linear microscopic utility of leisure.
Published 2014“…Consequently, <i>TA</i> no longer decreases but may even increase with price (A, lower panel). …”
-
16
-
17
IgG-mediated systemic anaphylaxis decreased in BasoDTR mice.
Published 2013“…<p>(A) BasoDTR mice (n = 4 per group) were treated once i.p. with 25 or 50 µg/kg of DT or PBS at 4 days prior to and were i.v. injected with 500 µg rat anti-FcγRII/III (2.4G2) antibodies in 200 µl PBS. …”
-
18
-
19
-
20